Bevacizumab for Patients with Recurrent Multifocal Glioblastomas.

about

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas.

Item

http://www.wikidata.org/entity/Q47167281

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas.

@en

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas.

@nl

type

Item

label

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas.

@en

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas.

@nl

prefLabel

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas.

@en

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas.

@nl

P1476

Bevacizumab for Patients with Recurrent Multifocal Glioblastomas.

@en

P2093

Hans C Cieplik

http://www.w3.org/2001/XMLSchema#string

Joachim P Steinbach

http://www.w3.org/2001/XMLSchema#string

Kea Franz

http://www.w3.org/2001/XMLSchema#string

Oliver Bähr

http://www.w3.org/2001/XMLSchema#string

Stella Breuer

http://www.w3.org/2001/XMLSchema#string

P2860

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis

A randomized trial of bevacizumab for newly diagnosed glioblastoma

Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.

VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer.

Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme.

Bevacizumab for Patients with Recurrent Gliomas Presenting with a Gliomatosis Cerebri Growth Pattern.

Comprehensive molecular characterization of multifocal glioblastoma proves its monoclonal origin and reveals novel insights into clonal evolution and heterogeneity of glioblastomas.

Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma

Addition of Anti-Angiogenetic Therapy with Bevacizumab to Chemo- and Radiotherapy for Leptomeningeal Metastases in Primary Brain Tumors.

The cause of death in patients with glioblastoma is multifactorial: clinical factors and autopsy findings in 117 cases of supratentorial glioblastoma in adults.

P31

scholarly article

P356

10.3390/IJMS18112469

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Michael C Burger

Patrick N. Harter

P577

2017-11-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29156610

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

5713435

http://www.w3.org/2001/XMLSchema#string